[1]
Perletti, G. 2016. Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer. Archivio Italiano di Urologia e Andrologia. 88, 1 (Mar. 2016), 74-75. DOI:https://doi.org/10.4081/aiua.2016.1.74.